爱必妥联合放化or化疗食道癌2010ASCO.ppt
《爱必妥联合放化or化疗食道癌2010ASCO.ppt》由会员分享,可在线阅读,更多相关《爱必妥联合放化or化疗食道癌2010ASCO.ppt(46页珍藏版)》请在咨信网上搜索。
1、爱必妥治疗食道癌2010ASCO更新概述食道癌占全球癌症死因第6位亚洲国家常见病理类型:鳞状细胞癌西方国家常见病理类型:腺癌50-80的食道癌有EGFR表达C-225联合同步放化疗治疗胃食道癌治疗方案:C-225:400mg/m2(第1周),250mg/m2(第2-6周)紫杉醇紫杉醇:50mg/m2/w +卡铂卡铂 AUC2/w(第1-6周)同步放疗同步放疗:DT 50.4Gy/28F Safran H,et al.Int.J.Radiat Oncol Biol Phys.2007.10一项II期临床初步结果爱必妥+紫杉醇+顺铂+放疗,用于局部晚期食道鳞癌治疗时间7周39例入组,32例完成计划
2、,CR15例,PR15例,SD1例,有1例未评估有效率RR为93.8%K-ras均为野生型结论此爱必妥+放化疗方案治疗食道癌,耐受性好,有效率达预期,毒性可预测爱必妥+放化疗用于食道癌新辅助术前爱必妥200mg/m2/周+放化疗,术后再用4-6周,共用16周15例入组,7例R0切除(4例CR,1例PR,2例SD)3例经影像学及内镜证实CR,但无手术指证8/15有效,2年无复发率40%(6/15)另有3例一年无复发爱必妥为基础的爱必妥为基础的新辅助化疗新辅助化疗在食道癌和胃癌在食道癌和胃癌提高手术切除率提高手术切除率55例食道癌,5例胃癌爱必妥+PC方案(紫杉醇+卡铂)每周657例患者完成治疗,
3、44例手术,13例内镜下重分期,(6例不能手术,7例减瘤)常见毒性有食道粘膜炎、皮疹等内镜证实的CR22%,接近CR22%(残余癌镜下1个),PR25%,SD30%20例降期爱必妥为基础的新辅助显著降期,提高切除率,毒性有限爱必妥+放化疗治疗局晚不可切除食道癌(SWOG0414)爱必妥+CPT-11+顺铂+放疗的方案22例入组,17例可评价,1例CR,2例PR,3例SD2例死亡(猝死和消化道坏死)3级毒性48%,4级29%,主要有血红蛋白下降、疲劳、腹泻、恶心呕吐、脱水、厌食验证了入组病人的基因表达与其预后无相关性结论耐受性较差,但是初步结果令人鼓舞,因此,SWOG赞同进行RTOG 0436研
4、究,进一步确定西妥昔单抗能够作为食道癌基础用药。爱必妥治疗食管癌治疗模式有同步放化疗、新辅助爱必妥+化疗、新辅助爱必妥+放化疗小样本初步结果令人鼓舞最合适的治疗模式有待进一步研究安全性有待进一步观察爱必妥+FOLFOX治疗III期贲门及食道癌研究的中期分析有效率RR 28/36(66%),其中14例CR,14例PR,另5例SD18例失访的病人中14例一个月以上无进展主要毒性粘膜炎、呕吐、中性粒细胞减少伴发热、吞咽困难、过敏初步结果表明爱必妥+FOLFOX方案安全、有效,支持试验入组到计划的80例。爱必妥+紫杉醇+顺铂+放疗,放疗达到40Gy后,评价是否可手术切除,如不可切除,则放疗至60-66
5、Gy41例入组,20例手术,9例接受放疗至60-66GyITT人群的CR26%,随访10.3月,一年PFS率69%,OS率66%,主要的3/4级毒性是白细胞减少、中心粒细胞减少、食道炎、感染、皮疹、低镁血症。结论此爱必妥联合方案是安全有效的。爱必妥+放化疗治疗局部晚期食道鳞癌爱必妥为基础的治疗食道腺癌研究(E2205)爱必妥+奥沙利铂+5-Fu术前新辅助,术后继贯爱必妥+多西紫杉醇的治疗,观察有效率和毒性22例入组,18例手术,pCR的7例,13/18进行术后辅助化疗,12例完成(停止试验的由于放化疗后肺栓塞死亡、3腹泻死亡、败血症死亡)总共有7例死亡,4例由于ARDS(成人呼吸窘迫症),有2
6、例pCR的也死于此结论是有希望提高pCR率,毒性导致I期试验后终止。所有术后死亡都由于ARDS,死因正在研究。此方案不做推荐爱必妥+化疗治疗转移性食道癌及胃食道结合部癌(CALGB80403/ECOG1206)爱必妥分别+ECF/IC/FOLFOX治疗,ECF组和FOLFOX组都有超过40%的有效率,ECF组的更高,(58%VS 51%),IC组最低为38%。FOLFOX组的毒性更低结论C-225联合紫杉醇、卡铂的同步放化疗治疗胃食道癌患者是安全的C-225会增加皮肤毒性和过敏反应的发生率C-225最突出的皮肤毒性反应表现为:颜面部疼痛、掻痒的痤疮样皮疹,其他常见的部位包括胸部和腹部放疗区域皮
7、肤的皮疹并没有加重皮疹在治疗的第1-3周最为严重口服强力霉素、头孢氨苄可用于治疗皮疹Anopenlabel,multicenterclinicalstudyofcetuximabcombinedwithconcurrentchemoradiotherapyforlocallyadvancedesophagealsquamouscellcarcinoma:PreliminaryresultsofaphaseIItrial.J Clin Oncol 28,2010(suppl;abstr e14520)Author(s):J.M.Yu,J.H.Wang,X.Sun,L.H.Wang,G.Y.Zhu
8、,P.B.Feng,M.Ye,Y.Lu,S.C.Zhu,Z.X.Liao;Shandong Cancer Hospital and Institute,Jinan,China;Henan Cancer Hospital,Zhengzhou,China;Cancer Hosptial,Chinese Academy of Medical Science,Peking Union Medical College,Beijing,China;Beijing Cancer Hospital and Institute,Beijing,China;Jiangsu Cancer Hospital,Nanj
9、ing,China;Renjin Hospital Affiliated to Shanghai Jiaotong University,Shanghai,China;Department of Thoracic Oncology,State Key Laboratory of Biotherapy,Huaxi Hospital,Sichuan University,Chengdu,China;Fourth Hospital,Hebei Medical University,Shijiazhuang,China;University of Texas M.D.Anderson Cancer C
10、enter,Houston,TX Methods:Patients aged 18-70 years with stage II-III cervical,upper thoracic and midthoracic locally advanced nonresectable ESCC,ECOG performance status(PS)1 received cetuximab(400 mg/m2 on day1 before chemo-radiotherapy and then q1w7 weeks)plus paclitaxel(45 mg/m2 q1w7 weeks)and cis
11、platin(20 mg/m2 q1w7 weeks).Radiotherapy consisted of 59.4 Gy in 33 fractions in 7 weeks.The primary endpoint was overall response rate and secondary endpoints included time to disease progression,overall survival at 1 year and 3 year,toxicity and K-ras status.Planned accrual was 44 patients.Results
12、:.Preliminary data are available for 39 patients,including 31 male and 8 female.Median age was 58 years old.32 of all included patients finished the planned treatment.The overall response rate was 93.8%(complete response,n=15;partial response,n=15).Stable disease was observed in 1 patient,and 1 pati
13、ent has not been evaluated.The most relevant NCI-CTC grade 3 hematologic events were neutropenia(12.8%),febrile neutropenia(5.1%),and anemia(2.5%).Major nonhematologic toxicities were acneiform skin eruptions(grade 2 in 17.9%of patients)and dermatitis(64.1%).The acneiform skin eruptions mainly start
14、ed at the third week of cetuximab treatment.At the fourth week of radiotherapy,15.3%and 25.6%of the patients began to suffer from grade 1-2 dermatitis and mucositis,respectively.No grade 4 adverse event was observed.The K-ras status of all patients was wild-type genetype.Conclusions:The combined tre
15、atment modality of cetuximab plus concurrent chemoradiotherapy in locally advanced ESCC in China were well tolerated and resulted in promising response rates and a predictable toxicity profile.Highcompleteresponse(CR)rateand2-yearsurvivalrateswithnoevidenceofdisease(NED)inpatients(pts)withesophageal
16、carcinoma(EC)undergoingneoadjuvantcombinationofdocetaxelandcisplatin(DC)cetuximab(DCE)chemoradiationtherapy 2008 Gastrointestinal Cancers Symposium Session Type and Session Title:General Poster Session B Abstract No:121 Author(s):T.J.Fillos,P.Hentschel,K.T.Watkins,M.S.Karpeh,A.Meek,B.Kim,D.Francesch
17、i,S.Zee,S.Madajewicz Methods:Newly diagnosed pts with EC Stage 2A(T3)to 4 received weekly Docetaxel(D)25-30 mg/m2 and Cisplatin(C)25-30 mg/m2 for 6-8 weeks concurrently with radiation,5,040 cGy in 28 fractions.Cetuximab(E)200 mg/m2 Pts were scheduled 4-6 weeks later for surgery followed by the same
18、chemotherapy for total of 16 weeks of treatment.Pts were assessed for time to progression,overall survival and toxicities.Results:Fifteen pts treated in 2005-2006 underwent IRB approved evaluation;11 male and 4 female,median age of 62(range 44-78).Four had squamous cell(SCC)and 11 adenocarcinoma.Thi
19、rteen pts had stage IIa to III and 2 pts stage IV disease.Seven underwent R0 resections with 4 pCR and 1 pPR and 2 stable disease.Five progressed prior to surgery.Three pts(one with metastatic disease)had radiological and endoscopic proven CR but medically were not surgical candidates.A total of 8 p
20、ts out of 15 experienced RR(7 CRs and 1 PR-53%).Six out of 15 patients(40%)remain alive with NED after 2 years.An additional 3 pts have NED after 12 months.Cetuximab-basedneoadjuvantchemoradiationappearstofacilitatesurgicalresectioninpatientswithlocallyadvancedesophagealandgastriccancer.2008 Gastroi
21、ntestinal Cancers Symposium Session Type and Session Title:General Poster Session A Abstract No:33 Author(s):H.J.Wanebo,T.DiPetrillo,T.Kennedy Methods:Patients with locally advanced endoscopically and radiologically staged esophageal(55)and gastric cancer(5)(T2-4,N1-3,M0)were enrolled in an IRB appr
22、oved protocol including cetuximab 400 mg/M2 week 1,then 250 mg/M2/week x 5,paclitaxel 50mg/M2/week and carboplatin AUC=2 weekly x 6 with concurrent 50.4 Gy.Results:Fifty seven evaluable patients(50 M/7 F,median age 58 yrs)completed neoadjuvant therapy:44 had surgery,13 had restaging endoscopy only(6
23、 were inoperable and 7 declined surgery).Major toxicities were esophageal mucositis(grade 3/4 in 10 pts 20%,grade 3 dehydration in 5 pts,rash in 20 pts,and drug hypersensitivity in 2 pts)An endoscopically confirmed complete response was shown in 28 of 44 surgical pts(64%)and in 10 of 13 having endos
24、copy only.Major resections included Ivor Lewis(thoracoabdominal+/-cervical reconstruction 30 pts,transhiatal resection 12 pts and gastrectomy 2 pts).There was 1 post operative death.Significant primary site downstaging occurred in 20 pts(42%)with final stage T0(N0(8),T0N1-3(3),T1 N0(7),T1N1(2).Surgi
25、cal pathology included:complete path response(no residual cancer)in 10 pts(22%),a near CR(residual 1 microscopic foci only)in 10 pts(22%),partial response(50%regression)in 11 pts(25%)and persistent residual cancer in 13 pts(30%).Conclusion:Cetuximab-based neoadjuvant chemoradiation for locally advan
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 爱必妥 联合 or 化疗 食道癌 2010 ASCO
1、咨信平台为文档C2C交易模式,即用户上传的文档直接被用户下载,收益归上传人(含作者)所有;本站仅是提供信息存储空间和展示预览,仅对用户上传内容的表现方式做保护处理,对上载内容不做任何修改或编辑。所展示的作品文档包括内容和图片全部来源于网络用户和作者上传投稿,我们不确定上传用户享有完全著作权,根据《信息网络传播权保护条例》,如果侵犯了您的版权、权益或隐私,请联系我们,核实后会尽快下架及时删除,并可随时和客服了解处理情况,尊重保护知识产权我们共同努力。
2、文档的总页数、文档格式和文档大小以系统显示为准(内容中显示的页数不一定正确),网站客服只以系统显示的页数、文件格式、文档大小作为仲裁依据,平台无法对文档的真实性、完整性、权威性、准确性、专业性及其观点立场做任何保证或承诺,下载前须认真查看,确认无误后再购买,务必慎重购买;若有违法违纪将进行移交司法处理,若涉侵权平台将进行基本处罚并下架。
3、本站所有内容均由用户上传,付费前请自行鉴别,如您付费,意味着您已接受本站规则且自行承担风险,本站不进行额外附加服务,虚拟产品一经售出概不退款(未进行购买下载可退充值款),文档一经付费(服务费)、不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
4、如你看到网页展示的文档有www.zixin.com.cn水印,是因预览和防盗链等技术需要对页面进行转换压缩成图而已,我们并不对上传的文档进行任何编辑或修改,文档下载后都不会有水印标识(原文档上传前个别存留的除外),下载后原文更清晰;试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓;PPT和DOC文档可被视为“模板”,允许上传人保留章节、目录结构的情况下删减部份的内容;PDF文档不管是原文档转换或图片扫描而得,本站不作要求视为允许,下载前自行私信或留言给上传者【精****】。
5、本文档所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用;网站提供的党政主题相关内容(国旗、国徽、党徽--等)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。
6、文档遇到问题,请及时私信或留言给本站上传会员【精****】,需本站解决可联系【 微信客服】、【 QQ客服】,若有其他问题请点击或扫码反馈【 服务填表】;文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“【 版权申诉】”(推荐),意见反馈和侵权处理邮箱:1219186828@qq.com;也可以拔打客服电话:4008-655-100;投诉/维权电话:4009-655-100。